Cross-talk between Epstein-Barr virus and microenvironment in the pathogenesis of lymphomas

Seminars in Cancer Biology

Volumn 34, Issue , 2015, Pages 58-69

  Dolcetti, Riccardo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Epstein Barr virus; Exosome; Immune response; Lymphoma; Microenvironment

Indexed keywords

INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; BIOLOGICAL MARKER;

ANGIOGENESIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL GROWTH; CELL SURVIVAL; DENDRITIC CELL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; EXOSOME; LYMPHOID CELL; LYMPHOMA; MACROPHAGE; MALARIA FALCIPARUM; MOLECULAR INTERACTION; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; STROMA CELL; TUMOR MICROENVIRONMENT; VIRUS REACTIVATION; ANIMAL; BYSTANDER EFFECT; CELL COMMUNICATION; COMPLICATION; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VIROLOGY; VIRUS CELL TRANSFORMATION;

ANIMALS; B-LYMPHOCYTES; BIOMARKERS; BYSTANDER EFFECT; CELL COMMUNICATION; CELL TRANSFORMATION, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; EXOSOMES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOMODULATION; LYMPHOMA; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84942297160     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.04.006     Document Type: Review

References (138)

1. Scott D.W., Gascoyne R.D. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014, 14:517-534.
2. Shain K.H., Dalton W.S., Tao J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene 2015, [Epub ahead of print].
3. Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004, 4:757-768.
4. Dolcetti R., Dal Col J., Martorelli D., Carbone A., Klein E. Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas. Semin Cancer Biol 2013, 23:441-456.
5. Roughan J.E., Thorley-Lawson D.A. The intersection of Epstein-Barr virus with the germinal center. J Virol 2009, 83:3968-3976.
6. Dojcinov S.D., Venkataraman G., Pittaluga S., Wlodarska I., Schrager J.A., Raffeld M., et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 2011, 117:4726-4735.
7. Ma C.S., Pittaluga S., Avery D.T., Hare N.J., Maric I., Klion A.D., et al. Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease. J Clin Invest 2006, 116:322-333.
8. Chaganti S., Ma C.S., Bell A.I., Croom-Carter D., Hislop A.D., Tangye S.G., et al. Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients. Blood 2008, 112:672-679.
9. Vockerodt M., Yap L.F., Shannon-Lowe C., Curley H., Wei W., Vrzalikova K., et al. The Epstein-Barr virus and the pathogenesis of lymphoma. J Pathol 2015, 235:312-322.
10. Thorley-Lawson D.A., Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004, 350:1328-1337.
11. Iwakiri D., Takada K. Role of EBERs in the pathogenesis of EBV infection. Adv Cancer Res 2010, 107:119-136.
12. Pratt Z.L., Kuzembayeva M., Sengupta S., Sugden B. The microRNAs of Epstein-Barr Virus are expressed at dramatically differing levels among cell lines. Virology 2009, 386:387-397.
13. Vereide D.T., Seto E., Chiu Y.F., Hayes M., Tagawa T., Grundhoff A., et al. Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene 2014, 33:1258-1264.
14. Qiu J., Cosmopoulos K., Pegtel M., Hopmans E., Murray P., Middeldorp J., et al. A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia. PLoS Pathog 2011, 7:e1002193.
15. Wang D., Liebowitz D., Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985, 43:831-840.
16. Kilger E., Kieser A., Baumann M., Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998, 17:1700-1709.
17. Floettmann J.E., Eliopoulos A.G., Jones M., Young L.S., Rowe M. Epstein-Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions. Oncogene 1998, 17:2383-2392.
18. Uchida J., Yasui T., Takaoka-Shichijo Y., Muraoka M., Kulwichit W., Raab-Traub N., et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 1999, 286:300-303.
19. Fruehling S., Longnecker R. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 1997, 235:241-251.
20. Fukuda M., Longnecker R. Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation. J Virol 2005, 79:8655-8660.
21. Westhoff S.D., Sugden B. Potential cellular functions of Epstein-Barr nuclear antigen 1 (EBNA1) of Epstein-Barr virus. Viruses 2013, 5:226-240.
22. Zimber-Strobl U., Strobl L.J. EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Semin Cancer Biol 2001, 11:423-434.
23. Kohlhof H., Hampel F., Hoffmann R., Burtscher H., Weidle U.H., Holzel M., et al. Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells. Blood 2009, 113:5506-5515.
24. Iwakiri D. Epstein-Barr virus-encoded RNAs: key molecules in viral pathogenesis. Cancers (Basel) 2014, 6:1615-1630.
25. Kang M.S., Kieff E. Epstein-Barr virus latent genes. Exp Mol Med 2015, 47:e131.
26. Montone K.T., Hodinka R.L., Salhany K.E., Lavi E., Rostami A., Tomaszewski J.E. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease. Mod Pathol 1996, 9:621-630.
27. Hong G.K., Gulley M.L., Feng W.H., Delecluse H.J., Holley-Guthrie E., Kenney S.C. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol 2005, 79:13993-14003.
28. Mahot S., Sergeant A., Drouet E., Gruffat H. A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. J Gen Virol 2003, 84:965-974.
29. Morscio J., Dierickx D., Tousseyn T. Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?. Clin Dev Immunol 2013, 2013:150835.
30. Miyauchi K., Urano E., Yoshiyama H., Komano J. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma. Cancer Sci 2011, 102:1236-1241.
31. Vaysberg M., Lambert S.L., Krams S.M., Martinez O.M. Activation of the JAK/STAT pathway in Epstein Barr virus+-associated posttransplant lymphoproliferative disease: role of interferon-gamma. Am J Transplant 2009, 9:2292-2302.
32. Incrocci R., McCormack M., Swanson-Mungerson M. Epstein-Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas. J Gen Virol 2013, 94:1127-1133.
33. Piovan E., Tosello V., Indraccolo S., Cabrelle A., Baesso I., Trentin L., et al. Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood 2005, 105:931-939.
34. Tsai S.C., Lin S.J., Chen P.W., Luo W.Y., Yeh T.H., Wang H.W., et al. EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines. Blood 2009, 114:109-118.
35. Rowe M., Peng-Pilon M., Huen D.S., Hardy R., Croom-Carter D., Lundgren E., et al. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J Virol 1994, 68:5602-5612.
36. Cahir-McFarland E.D., Carter K., Rosenwald A., Giltnane J.M., Henrickson S.E., Staudt L.M., et al. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 2004, 78:4108-4119.
37. Kim J.H., Kim W.S., Park C. Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. Leuk Lymphoma 2012, 53:1586-1591.
38. Longnecker R. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?. Adv Cancer Res 2000, 79:175-200.
39. Campion E.M., Hakimjavadi R., Loughran S.T., Phelan S., Smith S.M., D'Souza B.N., et al. Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor beta1-induced B-cell apoptosis. J Virol 2014, 88:5001-5013.
40. Liu Y., Sattarzadeh A., Diepstra A., Visser L., van den Berg A. The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component. Semin Cancer Biol 2014, 24:15-22.
41. Skinnider B.F., Mak T.W. The role of cytokines in classical Hodgkin lymphoma. Blood 2002, 99:4283-4297.
42. Baumforth K.R., Birgersdotter A., Reynolds G.M., Wei W., Kapatai G., Flavell J.R., et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008, 173:195-204.
43. Marshall N.A., Culligan D.J., Tighe J., Johnston P.W., Barker R.N., Vickers M.A. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Exp Hematol 2007, 35:596-604.
44. Hudnall S.D., Betancourt E., Barnhart E., Patel J. Comparative flow immunophenotypic features of the inflammatory infiltrates of Hodgkin lymphoma and lymphoid hyperplasia. Cytometry B Clin Cytom 2008, 74:1-8.
45. Setsuda J., Teruya-Feldstein J., Harris N.L., Ferry J.A., Sorbara L., Gupta G., et al. Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol 1999, 155:257-265.
46. Teichmann M., Meyer B., Beck A., Niedobitek G. Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. J Pathol 2005, 206:68-75.
47. Oudejans J.J., Jiwa N.M., Kummer J.A., Horstman A., Vos W., Baak J.P., et al. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. Blood 1996, 87:3844-3851.
48. Baumforth K.R., Flavell J.R., Reynolds G.M., Davies G., Pettit T.R., Wei W., et al. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 2005, 106:2138-2146.
49. Takahara M., Kis L.L., Nagy N., Liu A., Harabuchi Y., Klein G., et al. Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3. Int J Cancer 2006, 119:2775-2783.
50. Yoshino K., Kishibe K., Nagato T., Ueda S., Komabayashi Y., Takahara M., et al. Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27. Br J Haematol 2013, 160:331-342.
51. Chuang H.C., Lay J.D., Hsieh W.C., Su I.J. Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target. Cancer Sci 2007, 98:1281-1287.
52. Tsimbouri P., Al-Sheikh Y., Drotar M.E., Cushley W., Wilson J.B. Epstein-Barr virus nuclear antigen-1 renders lymphocytes responsive to IL-2 but not IL-15 for survival. J Gen Virol 2008, 89:2821-2832.
53. Kis L.L., Takahara M., Nagy N., Klein G., Klein E. IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines. Blood 2006, 107:2928-2935.
54. Kis L.L., Salamon D., Persson E.K., Nagy N., Scheeren F.A., Spits H., et al. IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter. Proc Natl Acad Sci U S A 2010, 107:872-877.
55. Kis L.L., Gerasimcik N., Salamon D., Persson E.K., Nagy N., Klein G., et al. STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma. Blood 2011, 117:165-174.
56. Nagy N., Adori M., Rasul A., Heuts F., Salamon D., Ujvari D., et al. Soluble factors produced by activated CD4+ T cells modulate EBV latency. Proc Natl Acad Sci U S A 2012, 109:1512-1517.
57. Rowe M., Raithatha S., Shannon-Lowe C. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions. J Virol 2014, 88:12065-12076.
58. Cader F.Z., Vockerodt M., Bose S., Nagy E., Brundler M.A., Kearns P., et al. The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1. Blood 2013, 122:4237-4245.
59. Wang D., Liebowitz D., Wang F., Gregory C., Rickinson A., Larson R., et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 1988, 62:4173-4184.
60. Birkenbach M., Liebowitz D., Wang F., Sample J., Kieff E. Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines. J Virol 1989, 63:4079-4084.
61. Mohr C.F., Kalmer M., Gross C., Mann M.C., Sterz K.R., Kieser A., et al. The tumor marker Fascin is induced by the Epstein-Barr virus-encoded oncoprotein LMP1 via NF-kappaB in lymphocytes and contributes to their invasive migration. Cell Commun Signal 2014, 12:46.
62. Li A., Dawson J.C., Forero-Vargas M., Spence H.J., Yu X., Konig I., et al. The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol 2010, 20:339-345.
63. Schoumacher M., Goldman R.D., Louvard D., Vignjevic D.M. Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J Cell Biol 2010, 189:541-556.
64. Woodford N.L., Call D.R., Remick D.G., Rochford R. Model of angiogenesis in mice with severe combined immunodeficiency (SCID) and xenoengrafted with Epstein-Barr virus-transformed B cells. Comp Med 2004, 54:209-215.
65. Vacca A., Ribatti D., Iurlaro M., Albini A., Minischetti M., Bussolino F., et al. Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. Int J Clin Lab Res 1998, 28:55-68.
66. Ceccarelli S., Visco V., Raffa S., Wakisaka N., Pagano J.S., Torrisi M.R. Epstein-Barr virus latent membrane protein 1 promotes concentration in multivesicular bodies of fibroblast growth factor 2 and its release through exosomes. Int J Cancer 2007, 121:1494-1506.
67. Wang Z., Luo F., Li L., Yang L., Hu D., Ma X., et al. STAT3 activation induced by Epstein-Barr virus latent membrane protein1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 And ERK signaling. Eur J Cancer 2010, 46:2996-3006.
68. O'Neil J.D., Owen T.J., Wood V.H., Date K.L., Valentine R., Chukwuma M.B., et al. Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol 2008, 89:2833-2842.
69. Wakisaka N., Kondo S., Yoshizaki T., Murono S., Furukawa M., Pagano J.S. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol Cell Biol 2004, 24:5223-5234.
70. Cuninghame S., Jackson R., Zehbe I. Hypoxia-inducible factor 1 and its role in viral carcinogenesis. Virology 2014, 456-457:370-383.
71. Becker J., Covelo-Fernandez A., von B.F., Kube D., Wilting J. Specific tumor-stroma interactions of EBV-positive Burkitt's lymphoma cells in the chick chorioallantoic membrane. Vasc Cell 2012, 4:3.
72. Paydas S., Ergin M., Erdogan S., Seydaoglu G. Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leuk Res 2008, 32:1424-1430.
73. Webber J., Yeung V., Clayton A. Extracellular vesicles as modulators of the cancer microenvironment. Semin Cell Dev Biol 2015.
74. Raposo G., Nijman H.W., Stoorvogel W., Liejendekker R., Harding C.V., Melief C.J., et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996, 183:1161-1172.
75. Pegtel D.M., Cosmopoulos K., Thorley-Lawson D.A., van Eijndhoven M.A., Hopmans E.S., Lindenberg J.L., et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A 2010, 107:6328-6333.
76. Vallhov H., Gutzeit C., Johansson S.M., Nagy N., Paul M., Li Q., et al. Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro. J Immunol 2011, 186:73-82.
77. Meckes D.G., Gunawardena H.P., Dekroon R.M., Heaton P.R., Edwards R.H., Ozgur S., et al. Modulation of B-cell exosome proteins by gamma herpesvirus infection. Proc Natl Acad Sci U S A 2013, 110:E2925-E2933.
78. Nanbo A., Kawanishi E., Yoshida R., Yoshiyama H. Exosomes derived from Epstein-Barr virus-infected cells are internalized via caveola-dependent endocytosis and promote phenotypic modulation in target cells. J Virol 2013, 87:10334-10347.
79. Flanagan J., Middeldorp J., Sculley T. Localization of the Epstein-Barr virus protein LMP 1 to exosomes. J Gen Virol 2003, 84:1871-1879.
80. Gutzeit C., Nagy N., Gentile M., Lyberg K., Gumz J., Vallhov H., et al. Exosomes derived from Burkitt's lymphoma cell lines induce proliferation, differentiation, and class-switch recombination in B cells. J Immunol 2014, 192:5852-5862.
81. Verweij F.J., van Eijndhoven M.A., Hopmans E.S., Vendrig T., Wurdinger T., Cahir-McFarland E., et al. LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF-kappaB activation. EMBO J 2011, 30:2115-2129.
82. Canitano A., Venturi G., Borghi M., Ammendolia M.G., Fais S. Exosomes released in vitro from Epstein-Barr virus (EBV)-infected cells contain EBV-encoded latent phase mRNAs. Cancer Lett 2013, 337:193-199.
83. Takada K. Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis. Semin Cancer Biol 2012, 22:162-165.
84. Ahmed W., Philip P.S., Tariq S., Khan G. Epstein-Barr virus-encoded small RNAs (EBERs) are present in fractions related to exosomes released by EBV-transformed cells. PLOS ONE 2014, 9:e99163.
85. Iwakiri D., Zhou L., Samanta M., Matsumoto M., Ebihara T., Seya T., et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009, 206:2091-2099.
86. Altevogt P., Bretz N.P., Ridinger J., Utikal J., Umansky V. Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. Semin Cancer Biol 2014, 28:51-57.
87. Dukers D.F., Meij P., Vervoort M.B., Vos W., Scheper R.J., Meijer C.J., et al. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol 2000, 165:663-670.
88. Frisan T., Sjoberg J., Dolcetti R., Boiocchi M., V De R., Carbone A., et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 1995, 86:1493-1501.
89. Ariza M.E., Rivailler P., Glaser R., Chen M., Williams M.V. Epstein-Barr virus encoded dUTPase containing exosomes modulate innate and adaptive immune responses in human dendritic cells and peripheral blood mononuclear cells. PLOS ONE 2013, 8:e69827.
90. Haneklaus M., Gerlic M., Kurowska-Stolarska M., Rainey A.A., Pich D., McInnes I.B., et al. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol 2012, 189:3795-3799.
91. Ansari M.A., Singh V.V., Dutta S., Veettil M.V., Dutta D., Chikoti L., et al. Constitutive interferon-inducible protein 16-inflammasome activation during Epstein-Barr virus latency I, II, and III in B and epithelial cells. J Virol 2013, 87:8606-8623.
92. Toscano M.A., Bianco G.A., Ilarregui J.M., Croci D.O., Correale J., Hernandez J.D., et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007, 8:825-834.
93. Perone M.J., Larregina A.T., Shufesky W.J., Papworth G.D., Sullivan M.L., Zahorchak A.F., et al. Transgenic galectin-1 induces maturation of dendritic cells that elicit contrasting responses in naive and activated T cells. J Immunol 2006, 176:7207-7220.
94. Keryer-Bibens C., Pioche-Durieu C., Villemant C., Souquere S., Nishi N., Hirashima M., et al. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 2006, 6:283.
95. Klibi J., Niki T., Riedel A., Pioche-Durieu C., Souquere S., Rubinstein E., et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009, 113:1957-1966.
96. Mrizak D., Martin N., Barjon C., Jimenez-Pailhes A.S., Mustapha R., Niki T., et al. Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. J Natl Cancer Inst 2015, 107:363.
97. Kimura H., Hoshino Y., Hara S., Sugaya N., Kawada J., Shibata Y., et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis 2005, 191:531-539.
98. Li L., Liu D., Hutt-Fletcher L., Morgan A., Masucci M.G., Levitsky V. Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 2002, 99:3725-3734.
99. Walling D.M., Ray A.J., Nichols J.E., Flaitz C.M., Nichols C.M. Epstein-Barr virus infection of Langerhans cell precursors as a mechanism of oral epithelial entry, persistence, and reactivation. J Virol 2007, 81:7249-7268.
100. Savard M., Belanger C., Tardif M., Gourde P., Flamand L., Gosselin J. Infection of primary human monocytes by Epstein-Barr virus. J Virol 2000, 74:2612-2619.
101. Larochelle B., Flamand L., Gourde P., Beauchamp D., Gosselin J. Epstein-Barr virus infects and induces apoptosis in human neutrophils. Blood 1998, 92:291-299.
102. Isobe Y., Sugimoto K., Yang L., Tamayose K., Egashira M., Kaneko T., et al. Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. Cancer Res 2004, 64:2167-2174.
103. Wang Z.Y., Liu Q.F., Wang H., Jin J., Wang W.H., Wang S.L., et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood 2012, 120:2003-2010.
104. Savard M., Gosselin J. Epstein-Barr virus immunossuppression of innate immunity mediated by phagocytes. Virus Res 2006, 119:134-145.
105. Shimakage M., Sakamoto H. Macrophage involvement in Epstein-Barr virus-related tumors. Exp Ther Med 2010, 1:285-291.
106. Liu W.L., Lin Y.H., Xiao H., Xing S., Chen H., Chi P.D., et al. Epstein-Barr virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-kappaB pathways: impairment in T cell functions. J Virol 2014, 88:6660-6671.
107. Tardif M., Savard M., Flamand L., Gosselin J. Impaired protein kinase C activation/translocation in Epstein-Barr virus-infected monocytes. J Biol Chem 2002, 277:24148-24154.
108. Benharroch D., Guterman G., Levy I., Shaco-Levy R. High content of Langerhans cells in malignant lymphoma - incidence and significance. Virchows Arch 2010, 457:63-67.
109. Braz-Silva P.H., Vitale S., Butori C., Guevara N., Santini J., Magalhaes M., et al. Specific infiltration of langerin-positive dendritic cells in EBV-infected tonsil, Hodgkin lymphoma and nasopharyngeal carcinoma. Int J Cancer 2011, 128:2501-2508.
110. Jeziorski E., Senechal B., Molina T.J., Devez F., Leruez-Ville M., Morand P., et al. Herpes-virus infection in patients with Langerhans cell histiocytosis: a case-controlled sero-epidemiological study, and in situ analysis. PLoS ONE 2008, 3:e3262.
111. Windebank K., Nanduri V. Langerhans cell histiocytosis. Arch Dis Child 2009, 94:904-908.
112. Coleman C.B., Wohlford E.M., Smith N.A., King C.A., Ritchie J.A., Baresel P.C., et al. Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines. J Virol 2015, 89:2301-2312.
113. Lee S.P., Chan A.T., Cheung S.T., Thomas W.A., CroomCarter D., Dawson C.W., et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol 2000, 165:573-582.
114. Marshall N.A., Christie L.E., Munro L.R., Culligan D.J., Johnston P.W., Barker R.N., et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103:1755-1762.
115. Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006, 66:5716-5722.
116. Ma Y., Visser L., Blokzijl T., Harms G., Atayar C., Poppema S., et al. The CD4+. Lab Invest 2008, 88:482-490.
117. Thomas J.A., Hotchin N.A., Allday M.J., Amlot P., Rose M., Yacoub M., et al. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 1990, 49:944-953.
118. Perera S.M., Thomas J.A., Burke M., Crawford D.H. Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease. J Pathol 1998, 184:177-184.
119. Konforte D., Simard N., Paige C.J. Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells. Virology 2008, 374:100-113.
120. Ding B.B., Bi E., Chen H., Yu J.J., Ye B.H. IL-21 and CD40L synergistically promote plasma cell differentiation through upregulation of Blimp-1 in human B cells. J Immunol 2013, 190:1827-1836.
121. Veronese M.L., Veronesi A., D'Andrea E., Del M.A., Indraccolo S., Mazza M.R., et al. Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. I. T lymphocyte requirement for B cell tumor generation. J Exp Med 1992, 176:1763-1767.
122. Johannessen I., Asghar M., Crawford D.H. Essential role for T cells in human B-cell lymphoproliferative disease development in severe combined immunodeficient mice. Br J Haematol 2000, 109:600-610.
123. Ma S.D., Xu X., Plowshay J., Ranheim E.A., Burlingham W.J., Jensen J.L., et al. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis. J Clin Invest 2015, 125:304-315.
124. Gloghini A., Dolcetti R., Carbone A. Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. Semin Cancer Biol 2013, 23:457-467.
125. Potup P., Kumsiri R., Kano S., Kalambaheti T., Looareesuwan S., Troye-Blomberg M., et al. Blood stage Plasmodium falciparum antigens induce immunoglobulin class switching in human enriched B cell culture. Southeast Asian J Trop Med Public Health 2009, 40:651-664.
126. Simone O., Bejarano M.T., Pierce S.K., Antonaci S., Wahlgren M., Troye-Blomberg M., et al. TLRs innate immunereceptors and Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) CIDR1alpha-driven human polyclonal B-cell activation. Acta Trop 2011, 119:144-150.
127. Donati D., Mok B., Chene A., Xu H., Thangarajh M., Glas R., et al. Increased B cell survival and preferential activation of the memory compartment by a malaria polyclonal B cell activator. J Immunol 2006, 177:3035-3044.
128. Chene A., Donati D., Guerreiro-Cacais A.O., Levitsky V., Chen Q., Falk K.I., et al. A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog 2007, 3:e80.
129. Donati D., Zhang L.P., Chene A., Chen Q., Flick K., Nystrom M., et al. Identification of a polyclonal B-cell activator in Plasmodium falciparum. Infect Immun 2004, 72:5412-5418.
130. Moormann A.M., Snider C.J., Chelimo K. The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma. Curr Opin Infect Dis 2011, 24:435-441.
131. Molyneux E.M., Rochford R., Griffin B., Newton R., Jackson G., Menon G., et al. Burkitt's lymphoma. Lancet 2012, 379:1234-1244.
132. Rickinson A.B. Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin Cancer Biol 2014, 26:99-115.
133. Iskra S., Kalla M., Delecluse H.J., Hammerschmidt W., Moosmann A. Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus. J Virol 2010, 84:3612-3623.
134. Younesi V., Shirazi F.G., Memarian A., Amanzadeh A., Jeddi-Tehrani M., Shokri F. Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay. Cytotechnology 2014, 66:95-105.
135. Ladell K., Dorner M., Zauner L., Berger C., Zucol F., Bernasconi M., et al. Immune activation suppresses initiation of lytic Epstein-Barr virus infection. Cell Microbiol 2007, 9:2055-2069.
136. Harsini S., Beigy M., Akhavan-Sabbagh M., Rezaei N. Toll-like receptors in lymphoid malignancies: double-edged sword. Crit Rev Oncol Hematol 2014, 89:262-283.
137. Noack J., Jordi M., Zauner L., Alessi D., Burch A., Tinguely M., et al. TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism. Cell Death Dis 2012, 3:e323.
138. Guo Y., Siewe B., Epeldegui M., Detels R., Landay A.L., Martinez-Maza O. TLR2-activated B cells are phenotypically similar to the abnormal circulating B cells seen preceding the diagnosis of AIDS-related NHL diagnosis. J Acquir Immune Defic Syndr 2013, 64:204-210.